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Abstract
Aims/hypothesis Accelerated migration and proliferation of
vascular smooth muscle cells (VSMCs) enhances arterial
restenosis after angioplasty in insulin resistance and diabetes.
Elevation of Src homology 2-containing protein tyrosine
phosphatase 1 (SHP-1) induces apoptosis in the microvascu-
lature. However, the role of SHP-1 in intimal hyperplasia and
restenosis has not been clarified in insulin resistance and
diabetes.
Methods We used a femoral artery wire injury mouse model,
rodent models with insulin resistance and diabetes, and patients
with type 2 diabetes. Further, we modulated SHP-1 expression
using a transgenic mouse that overexpresses SHP-1 in VSMCs
(Shp-1-Tg). SHP-1 agonists were also employed to study the
molecular mechanisms underlying the regulation of SHP-1 by
oxidised lipids.
Results Mice fed a high-fat diet (HFD) exhibited increased
femoral artery intimal hyperplasia and decreased arterial
SHP-1 expression compared with mice fed a regular diet.
Arterial SHP-1 expression was also decreased in Zucker fatty
rats, Zucker diabetic fatty rats and in patients with type 2
diabetes. In primary cultured VSMCs, oxidised LDL sup-
pressed SHP-1 expression by activating Mek-1 (also known
as Map2k1) and increased DNA methylation of the Shp-1
promoter. VSMCs from Shp-1-Tg mice exhibited impaired
platelet-derived growth factor (PDGF)-stimulated tyrosine
phosphorylation with a concomitant decrease in PDGF-
stimulated VSMC proliferation and migration. Similarly,
HFD-fed Shp-1-Tg mice and mice treated with the SHP-1
inducer, Icariside II, were protected from the development of
intimal hyperplasia following wire injury.
Conclusions/interpretation Suppression of SHP-1 by
oxidised lipids may contribute to the excessive VSMC prolif-
eration, inflammatory cytokine production and intimal hyper-
plasia observed in arteries from diabetes and insulin resis-
tance. Augmenting SHP-1 levels is a potential therapeutic
strategy to maintain stent patency in patients with insulin
resistance and diabetes.
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Introduction
A prominent feature in the pathology of restenosis and athero-
sclerosis is the increased number of vascular smooth muscle
cells (VSMCs) in the intima of arteries due to enhanced
VSMC migration and proliferation [1, 2]. The key role of
abnormal VSMC growth in the pathogenesis of arterial reste-
nosis is highlighted by the three- to fourfold reduction in
restenosis rates with the use of drug-eluting stents that target
smooth muscle cell proliferation and migration [3, 4].
However, even with the use of these stents, patients with dia-
betes still exhibit an increased risk of restenosis compared
with non-diabetic patients [5].
Multiple mechanisms have been proposed to explain the
excessive VSMC proliferation observed in diabetes and other
insulin-resistant states. Hyperglycaemia and dyslipidaemia are
thought to play important roles by increasing the expression of
mitogenic growth factors [6]. Indeed, elevated expression of
insulin, insulin-like growth factor-1 (IGF-1), platelet-derived
growth factor (PDGF) and fibroblast growth factor-2 (FGF2)
[7–9] has been associated with enhanced VSMC proliferation.
However, there is disagreement in the literature about whether
the expression of these growth factors is increased in the vas-
cular wall or plasma in the context of diabetes [10]. Thus, it is
still unclear if this mechanism drives excessive VSMC prolif-
eration in the diabetic milieu.
In contrast, the possibility of enhanced action of growth
factors through amplification of their intracellular signalling
cascades has not been studied in detail. Src homology-2-
containing protein tyrosine phosphatase (SHP-1) is a tyrosine
phosphatase that functions as a negative regulator of growth-
factor-dependent signalling. SHP-1 is a potent negative regu-
lator of growth-factor signalling but the expression of SHP-1
and its contribution to vascular restenosis in animal models of
obesity and type 2 diabetes have not been investigated.
In this report, we aimed to determine the expression level
of SHP-1 in the arterial wall in animal models and human
obesity and type 2 diabetes mellitus. Further, we studied the
effect of oxidised lipids on SHP-1 expression in VSMCs and
contribution to the excessive VSMC proliferation, inflamma-
tory cytokine production and intimal hyperplasia observed in
arteries leading to a high risk of restenosis in insulin resistance
and diabetes. Finally, we aimed to determine whether pharma-
cologically augmenting SHP-1 expression could be an effec-
tive therapeutic approach to reduce restenosis.
Methods
For detailed methods, please refer to the electronic supple-
mentary materials (ESM) Methods.
Animals and reagent All protocols for animal use and eutha-
nasia were reviewed and approved by the Animal Care
Committee of the Joslin Diabetes Center. The experiments
were in accordance with National Institutes of Health (NIH)
guidelines following the standards established by the Animal
Welfare Acts and by the documents entitled ‘Principles for
Use of Animals’ and ‘Guide for the Care and Use of
Laboratory Animals’. Male Zucker lean (ZL) rats, Zucker fat-
ty (ZF) rats, Zucker diabetic fatty (ZDF) and their control
(LEAN +/?) were from Charles River (Wilmington, MA,
USA). C57BL/6 mice were from Jackson Laboratory (Bar
Harbor, ME, USA). PDGF-BB was purchased from Sigma
(St Louis, MO, USA).
Procurement of human arteries This work was approved by
the regional ethics committee (Region Syddanmark, protocol
number ID S-20100044). All patients over the age of 18 years,
referred to coronary artery bypass grafting (CABG) surgery at
Odense University Hospital, Denmark were asked to partici-
pate. Type 2 diabetes was defined as a history of diabetes,
treatment with glucose-lowering medicine or HbA1c>6.5%
and absence of IA2 and GAD65 autoantibodies. Arteries from
a part of the internal thoracic artery were collected.
Perivascular tissue was removed and arterial rings were fixed
in formalin for paraffin embedding.
Generation of SM22α-promoter-driven Shp-1-overex-
pressing transgenic mouse line CMV promoter drives
1.57 kb Lox-stop-Lox (LSL) fragment followed by full-length
Shp-1 (also known as Ptpn6) cDNA cloned into Not1 and
Xho1 (Fig. 3a). The final construct was digested with BstBI
and Mlu and the 6.5 kb fragment was injected into blastocytes.
LSL-Shp-1 mice were crossbred with Sm22α-CreKI mice
(stock no. 006878, Jackson Laboratory) to generate mice over-
expressing Shp-1 specifically in VSMCs, maintained on
C57BL/6J background. Primers (see ESM Methods for
details) were used for LSL-Shp-1 genotyping.
Femoral artery wire injury and histological analysis
Bilateral wire injury of the femoral artery was performed as
previously described [11]. Mice were sacrificed on day 28
post arterial injury. Arteries were excised and paraffin-embed-
ded. Sections (5 μm) were stained using Verhoeff tissue
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elastin stain (Sigma) and were masked for the measurement of
the luminal, intimal and medial areas using NIH ImageJ
(Bethesda, MD, USA).
Mouse aortic smooth muscle cell culture Aortas were dis-
sected and digested with collagen II (Worthington, Columbia,
NJ, USA). The adventitia was removed and further digested
and grown in 20% DMEM. Cells at passage 2–3 and that had
been starved for 48 h were used for all the experiments.
VSMC transfection Small interfering RNA for scramble or
Mek1 (also known asMap2k1) (sc-29396; Santa Cruz, Dallas,
TX, USA) and Jnk (also known as Mapk8) (no. 6232; Cell
Signaling Beverly, MA, USA) were transfected at 10 nmol/l
using Basic Smooth Muscle Cells (SMC) Nucleofector Kit.
Methylation analysis of the Shp-1 promoter by bisulfite
sequencing Genomic DNA was extracted from VSMCs and
bisulfite conversion was performed using EZ DNA
Methylation Gold kit (Zymo Research, Irvine, CA, USA).
The CT-converted DNA was then amplified (see ESM
Methods for primer details). The PCR fragment was cloned
into a TOPO vector for DNA sequencing. Methylation was
analysed using BiQ Analyzer software (Max-Planck-Institut
für Informatik, Saarbrücken, Germany).
SHP-1 activity assay SHP-1 was immunoprecipitated with
2 μg anti-SHP-1 polyclonal antibody (Santa Cruz) from con-
trol and Shp-1-Tg VSMCs overnight, 20 μl Protein A/G
PLUS-Agarose (Santa Cruz) was added and beads were
washed and then assayed by RediPlate 96 EnzChek Tyrosine
Phosphatase Assay Kit (Molecular Probes, Eugene, OR,
USA).
Cell proliferation assays, cell cycle analysis and migration
assays Cell proliferation was measured using Click-iT EdU
Flow Cytometry Assay Kit (Invitrogen, Carlsbad, CA, USA).
The CellTiter 96 Non-Radioactive Cell Proliferation Assay
(MTT assay; Promega, Madison, WI, USA) was used for the
measurement of cell number. For cell cycle analysis, cells
were and digestedwith RNase A. Propidium iodide was added
before flow cytometry analysis. Migration was measured by
Transwell insert using CytoSelect 24-Well Cell Migration
Assay kit (Cell Biolabs, San Diego, CA, USA).
Quantitative real-time PCR (qPCR) analysis Total RNA
was isolated and purified and converted into cDNA. Shp-1,
Shp-2 (also known as Ptp11), Ptp1b (Ptpn1), Cyclin E1
(Ccne1),Mcp-1 (Ccl2) and 36B4 (Rplp0). qPCR primers were
used with SYBR Green Master mix kit and detection was
performed using the ABI PRISM 7900 Sequence Detection
System (Applied Biosystems, Foster City, CA, USA).
Relative change was determined using the ΔΔ method and
normalised to 36B4 (also known as Rplp0).
Western blotting Protein samples were electrophoresed in
Bio-Rad TGX precast gels, transferred to a nitrocellulose
membrane and incubated with primary antibodies (see ESM
Methods for details). For p-Akt and Akt, and p-ERK and ERK
(same molecular mass protein), two separate gels were used
for phosphorylated and unphosphorylated protein instead of
stripping the membrane to reprobe the other to avoid the inef-
ficiency of stripping. Quantitative densitometry was per-
formed using NIH Image J.
Immunofluorescent staining Mouse femoral arteries were
fixed, embedded in paraffin and 5 μm sections were stained
with antibodies (see ESM Methods for details). Photoshop
(San Jose, CA, USA) was used for the quantification of
SHP-1 expression levels in the media of arteries. For the Ki-
67 and macrophage (MAC2) staining, positive cells with the
overlay of Ki-67 or MAC2 (red) with smooth muscle cell
marker (green) and DAPI (nucleus) were counted.
Icariside II oral gavaging in HFD-fed mice Icariside II (Syd
Lab, Natick, MA, USA) was dissolved in 15% PEG 400
(Sigma) and given to mice fed a high-fat diet (HFD) via daily
oral gavaging. 15% PEG 400 was given to vehicle-treated
mice. Treatment started 1 day before femoral artery injury.
Statistics Comparison of two groups was made using un-
paired t test. Comparison of more than two groups was per-
formed by one-way ANOVA followed by the post hoc analy-
sis with unpaired t test to evaluate statistical significance be-
tween the two groups. The data are presented as means
±SEM, unless otherwise stated. Statistical significance was
defined as p<0.05.
Results
HFD feeding enhances femoral artery intimal hyperplasia
in response to wire injury To determine whether insulin re-
sistance and diabetes increased intimal hyperplasia, wire inju-
ry in the femoral artery was performed on mice fed either a
regular diet (RD) or an HFD (60% energy from fat) for
4 weeks starting from the age of 8 weeks. HFD-fed mice
exhibited hypercholesterolaemia, obesity and insulin resis-
tance as determined by measurement of plasma lipids and
insulin levels and intraperitoneal insulin tolerance (IP-ITT)
and glucose tolerance test (IP-GTT) (ESM Fig. 1a–c and
ESM Table 1). Intimal hyperplasia in response to wire injury
showed that the intimal area and intima/media ratio were in-
creased by 100% and 133%, respectively, in HFD-fed mice
compared with RD-fed mice (Fig. 1a).
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Insulin resistance and diabetes downregulates SHP-1 ex-
pression in rodent aorta and human arteries Expression of
SHP-1 in the aorta was measured in three models of obesity,
insulin resistance and type 2 diabetes, including mice with
diet-induced obesity, ZF rats and ZDF rats. SHP-1 protein
was significantly decreased in aortas from HFD-fed mice,
ZF rats and ZDF rats compared with their respective controls
(Fig. 1b–d). In contrast, expression of other protein tyrosine
phosphatases (PTPs) PTP1B and SHP-2 was not changed in
the femoral arteries fromHFD vs. RDmice or in the neointima
and media of injured femoral artery (ESM Fig. 1d, e). Thus,
SHP-1, but not other PTPs, is decreased in insulin resistance
and diabetes. SHP-1 protein levels were also significantly de-
creased in the media of mammary arteries from patients with
type 2 diabetes compared with non-diabetic patients (Fig. 1e)
as assessed by double immunostaining of SHP-1 and
α-smooth muscle actin (α-SMA). Clinical characteristics of
the patients with type 2 diabetes included elevated levels of
HbA1c, total cholesterol, LDL and triacylglycerol levels when
compared with individuals without type 2 diabetes (ESM
Table 2).
Effect of lipids and glucose on SHP-1 expression and its
mechanisms As HFD mice and ZF and ZDF rats exhibited
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Fig. 1 Insulin resistance and
diabetes induce severe intimal
hyperplasia in response to arterial
injury and downregulate SHP-1
expression in rodent aortas and
human arteries. (a) C57BL/6J
mice were fed either RD or HFD
for 4 weeks before injury was
performed; n= 5–6; scale bar,
50 μm. (b) C57BL/6J mice were
fed on either RD or HFD for
8 weeks; n= 7. (c, d) Aortas from
ZF and ZDF rats at 14 weeks of
age; n= 5. (e) Human mammary
arteries; scale bar, 50 μm; n= 6.
AU, arbitrary units; T2DM, type
2 diabetes. *p< 0.05 and
**p< 0.01 for indicated
comparison
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hyperlipidaemia, hyperglycaemia and hyperinsulinemia
(ESM Table 1 and ESM Fig. 1a–c), we evaluated the effects
of modified lipids and hyperglycaemia on the regulation of
SHP-1 expression in mouse aortic VSMCs in vitro. In primary
cultures of VSMCs from C57BL/6J mice, the expression of
Shp-1mRNA (Fig. 2a) and protein (Fig. 2b) was decreased by
oxidised LDL (oxLDL) and acetyl-LDL (acLDL). No change
in SHP-1 expression was observed when VSMCs were incu-
bated in high (25 mmol/l) vs. low (5.5 mmol/l) glucose con-
ditions (Fig. 2a, b) or were treated with insulin (ESM
Fig. 2a, b). In the presence of actinomycin D, the half-life of
Shp-1 mRNA in VSMCs was 4 h and was not changed by
treatment with oxLDL (Fig. 2c). Since oxLDL activates sev-
eral stress kinases, we studied the effect of oxLDL on the
activation of mitogen-activated protein kinase (MAPK)/extra-
cellular signal-regulated kinase (ERK) (MEK), p38MAPK
and c-Jun N-terminal kinase (JNK). All three were activated
by oxLDL (Fig. 2d). However, only silencingMek1 impaired
the ability of oxLDL to suppress SHP-1 expression (Fig. 2e, f
and ESM Fig. 3a); we did not observe any change in VSMCs
with p38αMAPK, p38βMAPK or JNK knockdown (ESM
Fig. 3b–e). Prior study has suggested downregulation of
SHP-1 expression could be mediated by increased DNA
methylation of its promoter in cancer cells [12]. To delineate
the mechanism underlying regulation of SHP-1 by oxLDL,
we studied the effect of oxLDL treatment on methylation at
the Shp-1 promoter. Bisulfite sequencing was performed on
the region of the Shp-1 promoter ranging between +593 and
+879 relative to the +1 transcription start site of the Shp-1
gene. We observed a 68% increase in unconverted cytosines
on the Shp-1 promoter in VSMCs treated with oxLDL vs
control (Fig. 2g, h), suggesting that DNA methylation was
increased in the Shp-1 promoter. Thus, the expression of
SHP-1 is decreased in diabetes potentially via oxLDL
induced-methylation of the Shp-1 promoter.
Generation and characterisation of Shp-1-Tg mice To sup-
port the idea that enhancing SHP-1 expression in VSMCs can
decrease intimal hyperplasia in insulin resistance and type 2
diabetes, we generated transgenic mice overexpressing SHP-1
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specifically in VSMCs (Fig. 3a). Shp-1 mRNA and protein
levels were increased more than twofold in aortas and VSMCs
of Shp-1-Tg mice compared with control mice (Fig. 3b–d).
Further, SHP-1 activity was increased twofold in VSMCs
from Shp-1-Tg mice compared with control mice (Fig. 3e).
In contrast, mRNA expression of other PTPs, Ptp1b and
Shp-2, was not changed in VSMCs from Shp-1-Tg mice vs.
control mice (ESM Fig. 4a).
SHP-1 overexpression inhibits the activation of PDGF, in-
sulin and FGF2 receptors and their downstream signalling
in VSMCs The mitogenic actions of growth factors such as
PDGF, FGF2 and insulin can affect VSMC migration and
proliferation [13–15]. These factors signal via receptor tyro-
sine kinases and their actions may be suppressed by SHP-1.
Thus, we determined whether overexpression of SHP-1
inhibited the activation of tyrosine kinase receptors. First, in
VSMCs isolated from Shp-1-Tg mice tyrosine phosphoryla-
tion of PDGF receptor- β (PDGFRβ) was significantly de-
creased in response to PDGF-BB (Fig. 4a). We then deter-
mined whether SHP-1 targets tyrosine phosphorylation at a
specific site of on PDGFRβ. Three tyrosine phosphorylation
sites (Tyr751, Tyr740, Tyr771) were reported to be stimulated
by PDGF-BB [16]. Tyr751 was significantly decreased in
VSMCs from Shp-1-Tg mice vs. control mice in response to
PDGF-BB (Fig. 4b). No difference was observed at Tyr740 or
Tyr771 (ESM Fig. 4b,c). Thus, SHP-1 inhibits the action of
PDGF-BB via targeting Tyr751. Activation of p-ERK by
PDGF-BB (0.1 and 0.5 ng/ml) was decreased significantly
in VSMCs from Shp-1-Tg mice (Fig. 4c, d). Interestingly, no
difference was observed in Akt activation (p-Akt) between
control mouse and Shp-1-Tg mouse VSMCs at basal or with
PDGF stimulation (Fig. 4e).
FGF2 signalling in VSMCs was also studied because activat-
ed platelets secrete FGF2, resulting in VSMC migration and
proliferation during restenosis [14]. Both p-ERKand p-Akt levels
induced by FGF2 were significantly decreased in VSMCs from
Shp-1-Tg mice (Fig. 4f–h). Moreover, overexpression of SHP-1
also decreased insulin receptor β tyrosine phosphorylation and
p-ERK activation in response to insulin but insulin-stimulated
increases in p-Akt were not affected (ESM Fig. 4d–f).
Overexpression of SHP-1 in VSMCs inhibits the activation
of ERK and Akt in vivo The effect of overexpressing SHP-1
on p-ERK and p-Akt activation in vivo was studied in control
mice and Shp-1-Tg mice fed with HFD for 8 weeks before
femoral artery wire injury. No significant differences in body
weight, blood pressure, glucose tolerance, insulin tolerance or
plasma lipid concentrations between control and Shp-1-Tg
mice on HFD were observed (ESM Fig. 5a–g). Further, we
did not observe any difference in Shp-1 mRNA expression
between the sham and injury groups (ESM Fig. 6).
After 8 weeks on HFD, basal levels of p-ERK were similar
in control and Shp-1-Tg mice with sham injury (Fig. 5a, b). In
contrast, wire injury increased p-ERK expression in the fem-
oral artery twofold compared with control mice with sham
injury; this effect was significantly decreased in injured fem-
oral arteries from Shp-1-Tg mice (Fig. 5b). In addition, p-Akt
activation in Shp-1-Tg and control mice on HFD after wire
injury showed a fourfold increase; this was significantly
inhibited in Shp-1-Tg mice (Fig. 5c). Similarly, PDGF signal-
ling was enhanced in whole aortas from Shp-1-Tg mice stim-
ulated with PDGF-BB ex vivo (Fig. 5d–f).
Inhibition of cell proliferation, cell cycle progression and
migration in VSMCs from Shp-1-Tg mice PDGF-BB
increased cell proliferation in VSMCs from control mice as
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measured by BrdU incorporation and MTT assay. This effect
was reduced in VSMCs from Shp-1-Tg mice (Fig. 6a, b and
ESM Fig. 7a). Cell cycle analysis showed that PDGF-BB-
induced cell cycle progression from G1 to S phase was
inhibited by SHP-1 overexpression in VSMCs (Fig. 6c). In
keeping with these findings, PDGF-BB-induced cyclin E1
expression was decreased in VSMCs from Shp-1-Tg mice
(Fig. 6d). In contrast, the rate of VSMC apoptosis in Shp-1-
Tg mice was no different from that in control mice (ESM
Fig. 7b). We also assessed whether overexpression of SHP-1
could affect VSMC migration in response to PDGF-BB.
Migration assays showed that PDGF-induced migration was
reduced significantly in VSMCs from Shp-1-Tg mice com-
pared with control mice (Fig. 6e). Together, our findings
demonstrate that SHP-1 overexpression impairs mitogenic
signalling and limits growth-factor-induced proliferation and
migration of VSMCs.
Overexpression of SHP-1 in VSMCs inhibits the expres-
sion of inflammatory cytokine monocyte chemoattractant
protein-1 The number of inflammatory cells in the arterial
wall after injury may contribute to the severity of the resteno-
sis process [17]. Therefore, we characterised the effect of
PDGF-BB and FGF2 on the expression of monocyte
chemoattractant protein-1 (MCP-1) in VSMCs. FGF2 and
PDGF-BB increased Mcp-1 mRNA levels in VSMCs from
control mice but this induction was relatively impaired in
VSMCs from Shp-1-Tg mice (Fig. 6f). Mechanistically, a
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selective inhibitor of the p-ERK pathway, PD98059, signifi-
cantly inhibited the effect of FGF2 and PDGF-BB on Mcp-1
mRNA expression. The addition of wortmannin, an inhibitor
of the phosphoinositide 3-kinase/Akt pathway, impaired the
ability of PDGF-BB to induce MCP-1 expression but had no
effect on FGF2-dependent increases in MCP-1 (Fig. 6g).
Reduction of intimal hyperplasia in response to injury in
HFD-fed Shp-1-Tg mice To determine further the causal
relationship between decreased SHP-1 expression and accel-
erated intimal hyperplasia in insulin resistance and diabetes,
we studied the severity of intimal hyperplasia in response to
wire injury in the femoral artery from Shp-1-Tg and control
mice after 8 weeks of HFD feeding. The intimal area mea-
sured at 28 days after injury was reduced by 43% in Shp-1-Tg
mice compared with control mice. The ratio of intimal to me-
dial area also exhibited a reduction of 54% in Shp-1-Tg com-
pared with control mice on HFD (Fig. 7a).
Cell proliferation and macrophage content in the vascular
wall in response to injury To confirm that the suppression
of proliferat ion and pro-inflammatory cytokine
expression observed in SHP-1-overexpressing VSMCs
mediated the protective action of SHP-1 in arterial inju-
ry, we studied VSMC proliferation and macrophage
number in the wall of the femoral artery 8 days after
wire injury. Proliferating smooth muscle cells in the
injured artery, as determined by staining α-SMA and
Ki67, were counted in the media and neointima.
Double-immunostained cells were significantly less
abundant in Shp-1-Tg mice than in control mice
(Fig. 7b, c). Furthermore, the macrophage content of
media, as quantified by immunostaining for MAC2,
was significantly decreased in the media of the femoral
arteries from Shp-1-Tg mice compared with control
mice after injury (Fig. 7d, e).
Reduction of intimal hyperplasia in response to injury in
HFD mice treated with SHP-1 activator Icariside II was
reported to increase SHP-1 expression and have an antipro-
liferative effect in cancer cells [18]. Further, Icariside II
exhibited a reasonable pharmacokinetics profile in a single
dose oral gavaging study [19]. Thus, Icariside II was given
1 day before mice underwent arterial injury at a dose of
a
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100 mg/kg via daily oral gavaging for 28 days. In line with
previous studies [18], we observed that SHP-1 expression
was increased in the femoral arteries of Icariside II-treated
mice when compared with mice treated with vehicle
(Fig. 7f). Notably, we observed significant reduction in in-
timal area and the ratio of intimal to medial area at 28 days
after injury in HFD-fed mice treated with Icariside II when
compared with HFD-fed mice treated with vehicle
(Fig. 7g).
Discussion
The results from this study demonstrate that SHP-1 expression
in arterial VSMCs is decreased in insulin-resistant and diabet-
ic rodents and in patients with type 2 diabetes. In addition,
overexpression of SHP-1 in VSMCs, induced by both genetic
and pharmacological approaches, protected against intimal
hyperplasia in response to arterial wire injury by inhibiting
growth-factor-dependent signalling.
The mitogenic effects of diabetes and insulin resistance on
VSMCs in both restenosis and atherosclerosis have always
been puzzling considering the increases in apoptosis observed
in many other vascular cells including retinal pericytes,
podocytes and even endothelial cells [20–22]. Interestingly,
we previously demonstrated that diabetes and hyperglycaemia
upregulate the expression of SHP-1 in vascular contractile
cells from the capillaries of the retina and glomeruli [20, 22].
However, in the current study hyperglycaemia had no effect
on SHP-1 expression in arterial VSMCs, whereas modified
lipids suppressed SHP-1 expression. Thus, these findings
identify differential regulation of SHP-1 by hyperglycaemia
and lipids in the micro- and macrovasculature as a potential
mechanistic explanation for the dichotomous pathologies of
contractile cells in macro- and microvessels in diabetes [20,
23].
Dyslipidaemia rather than dysglycaemia seems to drive the
changes in SHP-1 expression in animal models of obesity and
diabetes as in vitro studies demonstrated that treatment with
modified lipids, but not hyperglycaemia suppressed SHP-1
expression. The pathogenic effects of hyperlipidaemia on cells
are mainly mediated by modified LDL such as oxLDL and
acLDL. We found that both oxLDL and acLDL inhibited
SHP-1 expression indicating that decreased SHP-1 expression
in hyperlipidaemic status is not oxLDL-specific and another
modified LDL could also be involved. Further studies will be
needed to confirm that these findings are relevant to human
diseases. However, our finding, in a limited cohort, that SHP-
1 expression is suppressed in type 2 diabetes patients is
encouraging.
Overexpression of SHP-1 in VSMCs from RD-fed mice
decreased the mitogenic action of several growth factors in-
cluding PDGF-BB, FGF2 and insulin. SHP-1 overexpression
exerts this action via inhibition of tyrosine phosphorylation at
the receptor level via Tyr751 on PDGFRβ, thus inhibiting
activation of p-ERK and preventing growth-factor-induced
cell cycle progression. It has been reported that the phosphor-
ylation of Tyr751 is required for both phosphoinositide
3-kinase and GTPase-activating protein (GAP) binding in ep-
ithelial cells [16, 24]. Further studies are needed to determine
the mechanistic significance of the reduction in Tyr751 of
PDGFRβ in VSMCs.
Our study is consistent with previous findings of the inhib-
itory effect of SHP-1 on the ERK pathway [25] and PDGFR
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signalling [26] in VSMCs. The activation of p-Akt in response
to PDGF-BB and insulin stimulation of VSMCs was not
affected by SHP-1 overexpression. In contrast, stimulation
by PDGF in ex vivo experiments showed that the signalling
of both p-Akt and p-ERK were diminished and that SHP-1
overexpression could significantly reduce p-Akt and p-ERK
induction by arterial injury. It is possible that the in vivo effect
of SHP-1 alters the action of multiple growth factors in the
Akt pathway. Interestingly, potentiation of phosphatases up-
stream of Akt have previously been suggested as a therapeutic
strategy in the context of vascular injury and restenosis [27].
Our work validates this suggestion in the context of diabetes
and obesity. Elucidation of the role of regulatory phosphatases
other than SHP-1 may allow us to fine tune the function of
vascular mitogens and optimise growth-factor-dependent sig-
nalling in response to vascular injury [27–29].
Importantly, induction of SHP-1 overexpression in VSMCs
using both genetic and pharmacological approaches was suf-
ficient to normalise the response to wire injury in mice with
diet-induced obesity. These results indicate that therapeutic
intervention to induce gain of SHP-1 function or normalisa-
tion of SHP-1 levels in stents could decrease restenosis in
diabetes and obesity. While SHP-1 is a potential therapeutic
target, translational challenges exist. Kappert’s group have
shown that systemic administration of an SHP-1 inhibitor im-
proves insulin sensitivity in animal models of diet-induced
obesity [30]. Moreover, HFD increases SHP-1 in a number
of tissues [23]. Thus, future therapeutic strategies to activate
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SHP-1 and prevent vascular restenosis should consider
targeted delivery of SHP-1 modulators either via topical
application in the form of drug-eluting stents or cell-specific
delivery using targeted delivery strategies such as ligand-
conjugated nanoparticles [31].
In summary, our findings suggest a new perspective on
how diabetes and insulin resistance increase the proliferation
and migration of VSMCs. oxLDL-mediated downregulation
of SHP-1 enhances growth-factor signalling in insulin resis-
tance and diabetes and enhances intimal hyperplasia in re-
sponse to arterial injury. These results support manipulation
of SHP-1 activity or expression as a novel therapeutic
approach to prevent restenosis and improve angioplasty out-
comes in patients with insulin resistance and diabetes.
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